Lacosamide Sugar Free Alissa (Lacosamide)

Lacosamide is an anticonvulsant that modulates neuronal sodium channels in epilepsy.

• Partial‑onset seizures: reduces seizure frequency and severity.
• Adjunct therapy in epilepsy: improves overall seizure control when combined with other antiepileptics.
• Focal epilepsy: provides additional reduction in seizure episodes.

• Lacosamide enhances the slow inactivation of voltage‑gated sodium channels, which stabilises hyper‑excitable neuronal membranes and diminishes repetitive neuronal firing. By selectively targeting the sodium channel’s slow inactivation phase, it reduces the propagation of epileptiform activity without markedly affecting normal neuronal conduction.

Lacosamide may cause a range of adverse reactions, from mild to serious.

Common Side Effects

• Dizziness: transient feeling of light‑headedness.
• Nausea: mild gastrointestinal upset.
• Headache: occasional tension‑type headache.
• Fatigue: increased tiredness or lack of energy.
• Blurred vision: temporary visual disturbances.
• Diplopia: double vision in some patients.

Serious or Rare Side Effects

• Suicidal ideation: emergence of depressive thoughts or self‑harm tendencies.
• Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Cardiac arrhythmia: alterations in heart rhythm, especially in patients with pre‑existing conduction disorders.
• Respiratory depression: marked reduction in breathing effort.
• Hypersensitivity reactions: including anaphylaxis or severe rash.
• Elevated liver enzymes: indicating potential hepatic stress.

Before prescribing Lacosamide, clinicians should consider several safety factors.

• Renal impairment: adjust dose in patients with reduced kidney function.
• Hepatic impairment: monitor liver function and consider dose modification.
• Cardiac conduction disorders: avoid in patients with known PR‑interval prolongation.
• Pregnancy: safety category unknown; weigh potential benefits against risks.
• Concomitant CNS depressants: monitor for enhanced sedation or dizziness.
• Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Lacosamide can interact with other medicines, requiring careful management.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., carbamazepine, phenytoin, phenobarbital): may markedly reduce lacosamide plasma levels.
• Other sodium channel blockers (e.g., lamotrigine, phenytoin): increase risk of CNS depression and cardiac effects.
• QT‑prolonging agents (e.g., quinidine, sotalol): may exacerbate arrhythmia risk.

Moderate Interactions (Monitor Closely)

• Oral contraceptives: lacosamide may decrease hormonal efficacy; consider alternative contraception.
• Alcohol: combined use can enhance dizziness and sedation.
• Additional antiepileptics: dose adjustments may be needed to maintain therapeutic balance.